Prognostic biomarker

Baseline Circulating Tumor DNA as a Prognostic Biomarker in Untreated Follicular Lymphoma: Insights from the GALLIUM Trial

By MedXY 04/27/2026

Baseline ctDNA levels predict early progression and poor survival in untreated follicular lymphoma, outperforming traditional risk scores like FLIPI. This study highlights ctDNA's potential as a stratification tool in clinical trials.

AI Oncology Pathology & Lab Medicine Specialties

Enhancing Melanoma Prognosis: AI-Driven Quantification of Tumor-Infiltrating Lymphocytes Outperforms Traditional Pathology

By MedXY 10/21/2025

This study demonstrates that an AI algorithm provides more reproducible and prognostically relevant assessment of tumor-infiltrating lymphocytes in melanoma compared to traditional pathologist methods, offering a promising tool to improve clinical decision-making.

Clinical Updates news Oncology

Total Tumor Volume: A Superior Predictor of Survival and Chemotherapy Response in Colorectal Cancer Liver Metastases

By MedXY 09/20/2025

This study reveals that total tumor volume (TTV) more accurately predicts overall survival and response to induction chemotherapy than RECIST1.1 in colorectal cancer liver metastases, offering a promising tool for personalized treatment decisions.

Cardiology news Pathology & Lab Medicine Specialties

NT-proBNP as a Prognostic Biomarker for Mortality in Ischemic Stroke: Insights from a Comprehensive Meta-Analysis

By MedXY 08/21/2025

This systematic review and meta-analysis evaluates NT-proBNP's accuracy in predicting mortality among ischemic stroke patients, revealing moderate to high prognostic performance with potential clinical utility in risk stratification.